Stay updated on Nivolumab in Advanced Lung Cancer: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Advanced Lung Cancer: Clinical Trial page.

Latest updates to the Nivolumab in Advanced Lung Cancer: Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added and the previous funding-status notice (Revision: v3.4.1) was removed.SummaryDifference0.2%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the NIH Clinical Center's status with a link to cc.nih.gov and opm.gov. Updated the site revision from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check28 days agoChange DetectedThe changes are minor UI and wording updates: the glossary is now shown, and several small label and version-text updates (including capitalization of 'Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0') were made; no study content or results were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 from the page's revision notes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations were updated: new site locations across multiple states and Canadian provinces were added, and several existing locations were removed.SummaryDifference2%

- Check92 days agoChange DetectedThe page now includes a note that publications are automatically filled from PubMed and may not be about the study, and the revision label has been updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Nivolumab in Advanced Lung Cancer: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Advanced Lung Cancer: Clinical Trial page.